HIV-Infected Individuals
Conditions
Brief summary
This is a multi-site phase 1 study of the safety, immunologic and virologic responses of ex vivo expanded donor-derived (DD) HIV-1 multi-antigen specific T-cell (HST) with non-escaped epitope targeting (NEET) therapy as a therapeutic strategy in HIV-infected individuals following Allogeneic Bone Marrow Transplantation (alloBMT).
Detailed description
The primary objective of this study is to evaluate the safety of donor-derived allogeneic expanded HIV-specific T-cell therapy (DD HST-NEETs) in HIV-infected alloBMT recipients on ART. Eligible donors will undergo a blood draw of up to 300mL to allow production of allogeneic DD HST-NEETs. Participants who meet specified inclusion criteria including neutrophil recovery post-transplant and for whom donor products have passed release testing will receive DD HST-NEETs at a dose of 2x107/m2 within 30 days of screening visit.
Interventions
BIOLOGICALDD HST-NEETs
HIV-infected individuals following Allogeneic Bone Marrow Transplantation (alloBMT) will be treated with DD HST-NEETS therapy. Participants and donors will be screened for eligibility. Eligible donors will undergo a blood draw of up to 300mL to allow production of allogeneic DD HST-NEETs. Participants, who meet specified inclusion criteria including neutrophil recovery post-transplant and for whom donor products have passed release testing, will receive DD HST-NEETs at a dose of 2x107/m2 within 30 days of screening visit.
Sponsors
Catherine Bollard
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Participant Inclusion Criteria at Screening: * Age ≥18 years. * Confirmation of HIV-1 infection. Any licensed ELISA test kit which is confirmed by Western blot or Multispot HIV-1/HIV-2 assay prior to screening. HIV culture, HIV antigen, plasma HIV RNA, or a second antibody test by a method other than ELISA is acceptable as an alternative confirmatory test. * On effective antiretroviral therapy. * Ability and willingness of participant to continue and be compliant with ART throughout the study. * Hematologic malignancy that qualifies for standard of care alloBMT according to JHU criteria. * Potential participant must have adequate organ function for standard of care alloBMT according to JHU criteria. * No active HCV infection. (If seropositive, participant must have no measureable HCV RNA within 30 days of enrollment). * No active HBV infection (If seropositive, participant must have no measureable HBV DNA or HBsAg+ within 30 days of enrollment). * Ability and willingness of participant to give written informed consent. * Ability and willingness to communicate effectively with study personnel; considered reliable, willing, and cooperative in terms of compliance with the Protocol requirements. * Ability and willingness to provide adequate locator information and contact information for at least 2 adults who can reach the participant within 24 hours Participant Inclusion Criteria for DD HST-NEETs Infusion: * Karnofsky score of ≥ 70. * ANC ≥ 250/µL. * Bilirubin ≤ 2x upper limit normal or direct bilirubin normal. * AST ≤ 3x upper limit normal. * Serum creatinine ≤ 2x upper limit normal. * Hgb ≥ 7.0 g/dL. * Pulse oximetry of \> 90% on room air. * Negative pregnancy test in female participants if applicable (childbearing potential). * Written informed consent signed by participant or guardian. * Steroids less or equal to 0.5 mg/kg/day prednisone. Donor Inclusion Criteria for Procurement for DD HST-NEETS Manufacturing: * Donors for allogeneic (i.e. HLA matched or mismatched related or unrelated) hematopoietic cell transplants who have fulfilled eligibility for and consented to stem cell donation as per JHU standard operating procedures. * Donor must be in good health based on institutional guidelines. * Female donors of childbearing age must have a negative pregnancy test and must not be lactating. * It is understood that medical clearance from the donor will be sought within the timeline per the National Marrow Donor Program (NMDP) rules. * The hematopoietic cell donor will have already been selected by the JHU BMT Donor Selection Committee. * Donor or parent/guardian capable of providing informed consent
Exclusion criteria
Participant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Any ≥ Grade 3 Adverse Events (as defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0) | 45 days | Any ≥ Grade 3 Adverse Events will be measured by number of participants who experience Dose Limiting Toxicity which is attributable to the DD HST-NEETS administration. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The feasibility of manufacturing of DD HST-NEETs | 3 years | Feasibility of the manufacturing process will be measured by generation of the cells in 4 or more donors (i.e., a rate of 50% of more). |
| The HIV reservoir measurements | 3 years | Summarize the HIV reservoir measurements over the pre-BMT, pre-DD HST-NEETs infusion, post-infusion period to assess any change in the HIV reservoir following infusion. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORRichard Ambinder, MD, PhD
Johns Hopkins University
PRINCIPAL_INVESTIGATORMichael Keller, MD
CNMC
Outcome results
None listed